Renal function, serum sodium level, and outcomes in hospitalized systolic heart failure patients

An analysis of the COAST study

Jin Joo Park (MD)a, In-Ho Chae (MD, PhD)a, Dong-Ju Choi (MD, PhD)a,∗, Seok-Min Kang (MD, PhD)b, Byung-Su Yoo (MD, PhD)c, Ju-Yen Hwang (MD, PhD)l, Shing-Jong Lin (MD, PhD)l, Ming-Shien Wen (MD, PhD)f, Jian Zhang (MD, PhD)g, Junbo Ge (MD, PhD)h, on behalf of the COAST investigators

Abstract
Both renal function and serum sodium level are well-known prognostic markers in heart failure (HF) patients. We investigated the prognostic value of the renal impairment (RI) stratified by the serum sodium level in systolic HF patients.

The Clinical Characteristics and Outcomes in Relation with Serum Sodium Level in Asian Patients Hospitalized for Heart Failure (the COAST) Study enrolled hospitalized systolic HF patients (ejection fraction<45%) in South Korea, Taiwan, and China. Twelve-month mortality was stratified according to the renal function and serum sodium level.

Of 1462 enrolled patients, 716 patients (49%) had RI (GFR<60 mL/min/1.73 m2), and they had higher 12-month mortality than those without RI (22.8% vs. 10.9%, P<0.001). Furthermore, 676 patients (46%) had low sodium level defined as Na<139 mmol/L. The mortality rate was lowest in patients with normal renal function and high sodium level (7.4%), but highest in those with RI and low sodium level (26.1%) (P<0.001). Patients with both RI and low sodium level had a 3.8-times increased hazard for 12-month mortality (HR 3.80, 95% CI 2.06–7.05), whereas the low sodium level (HR, 2.95; 95% CI, 1.51–5.75) and RI (HR 3.08; 95% CI, 1.63–5.82) had similar hazard, suggesting that they might be equivalent risk factors.

In hospitalized Asian HF-patients both RI and low sodium level are independent risk factors. Patients with both RI and low serum sodium level are at the highest risk and may require meticulous medical care.

Abbreviations: EF = ejection fraction, GFR = glomerular filtration rate, HF = heart failure, NYHA = New York Heart Association, RAAS = renin–angiotensin–aldosterone system, RI = renal impairment.

Keywords: hospitalized heart failure, low sodium level, predictor of clinical outcomes, renal impairment

1. Introduction
Hospitlizations for acute heart failure (HF) are increasing. Among various risk factors for poor clinical outcomes, a low serum sodium level is relatively common and associated with increased mortality among hospitalized HF patients.[11–3] There are numerous interactions between heart and kidney. Patients with kidney disease have an increased risk for cardiovascular events,[14] and vice-versa. More than half of the HF patients show renal impairment (RI),[15–7] and HF-patients with RI have excess mortality.[8,9]

Thus both RI and low sodium levels are well-known risk factors for adverse outcomes in HF patients, and those patients confer a group of patients with notably high disease severity. However, the predictive value of RI complicated by a low sodium level has not been evaluated in hospitalized HF patients. Clarifying the risk could provide more precise risk stratification and the development of optimal therapeutic strategies in these patients.

In this multinational, multicenter study, we aim to clarify the magnitude of risk of RI and low sodium level contributing to outcomes in Asian hospitalized systolic HF patients.

2. Materials and methods
An Observational Study on the Clinical Outcomes in Relation with Serum Sodium Level in Asian Patients Hospitalized for Heart Failure (COAST) is a multinational, multicenter registry. The design and main outcomes have been previously reported elsewhere.[10] In brief, we included 1650 HF patients with an age of 18 years or older and a left ventricular ejection fraction (LV EF) of <45% who were hospitalized for acute HF at 8 centers in

* Correspondence: Dong-Ju Choi, Cardiovascular Center, Seoul National University Bundang Hospital Professor of Internal Medicine, College of Medicine, Seoul National University, Bundang, Seongnam Gyeonggi-do, Republic of Korea (e-mail: djchoi@snubh.org).

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Medicine (2016) 95(25):e3898
http://dx.doi.org/10.1097/MD.0000000000003898

OPEN

Observational Study

© 2016 Wolters Kluwer Health, Inc. All rights reserved.
Korea, Taiwan, and China since January 2009. Patients’ data on index admission, discharge, and 1-year follow-up were collected at each site by trained study coordinators and audit was performed by the COAST Registry Steering Committee. In this substudy, we enrolled patients in whom glomerular filtration rate (GFR) could be calculated. The study protocol was approved by the institutional review board (IRB) or ethics committee at each participating hospital, and the patient’s informed consent was waived by the IRB of each participating center. The study complied with Declaration of Helsinki.

The serum sodium and creatinine levels were measured at hospital admission. The low serum sodium level was defined as serum sodium less than the median, which was 139 mmol/L. Using the median as a cutoff value allowed that the comparing groups had a similar sample size. The estimated glomerular filtration rate (eGFR) was calculated from creatinine values using the Modified Diet in Renal Disease (MDRD) formula. Patients were assigned a kidney function stage using National Kidney Foundation cutoffs for degrees of renal failure: stage I (normal; GFR > 90 mL/min/1.73 m²); stage II (mild damage; GFR 60–89 mL/min/1.73 m²); stage III (moderate damage; GFR 30–59 mL/min/1.73 m²); stage IV (severe damage; GFR 15–29 mL/min/1.73 m²); or stage V (kidney failure; GFR <15 mL/min/1.73 m²). We defined renal impairment as GFR <60 mL/min/1.73 m².

The primary endpoint was the 12-month mortality according to the renal function and serum sodium levels. The secondary endpoints included the mortality rates at the index admission, 12-month rehospitalization rate, and the composite of mortality and/or rehospitalization.

Categorical variables were presented as numbers and frequencies and continuous variables as mean±standard deviation. For comparison between groups, the chi-square test was used for categorical variables. The Wilcoxon rank-sum test was used for comparisons of serum sodium with continuous measures.

A Cox-proportional hazard regression analysis was applied to identify the independent predictors of 12-month mortality after adjustment for significant covariates. Receiver operating characteristics (ROC) curve analysis was used to determine the optimal cut-offs of the risk factors. All data were analyzed using SAS® Version 9 (SAS Institute, Cary, NC) and SPSS version 17 (SPSS Inc., Chicago, IL). The statistical analysis was performed by professional statistical counsel.

3. Results

Of 1470 patients enrolled in the COAST main study, GFR could not be calculated in 8 patients, so that the data of 1462 patients were available for the current analysis. GFR was unimodally distributed at admission (median of 60 mL/min/1.73 m² and interquartile range, 45–78 mL/min/1.73 m²). So was the distribution of serum sodium level at admission (median, 139 mmol/L and IQR, 136 – 141 mmol/L). The distribution of kidney stages was 14.4%, 36.6%, 34.6%, 9.7%, and 4.7% for stage I, II, III, IV, and V, respectively.

Almost half of the patients (716 patients, 49%) had RI, in contrast only 11.8% of the patients reported as having “chronic kidney disease” at the hospital admission. Table 1 shows the demographic and baseline characteristics of the patients according to the renal function and serum sodium level. Patients with RI had more adverse clinical characteristics, such as older age, higher frequency of diabetes mellitus, hypertension, dyslipidemia, and advanced New York Heart Association (NYHA) Class. Patients with RI had higher prevalence of hyponatremia, but lower frequency of prescription of rennin-angiotensin-aldosterone system (RAAS) inhibitor, beta blocker, and mineralocorticoid antagonist.

During a 12-month clinical follow-up, 244 patients (16.7%) died. Patients who died had lower GFR (51.4±29.7 vs. 64.0±28.4 mL/min/1.73 m², P<0.001) and serum sodium level (136.7±5.7 vs. 138.6±4.3 mmol/L, P<0.001) than those who survived. When stratifying according to the kidney stages, the 12-month mortality rate was 11.0%, 19.4%, 32.1%, and 31.6% for stage I, II, III, IV, and V, respectively (P<0.001, linear-by-linear association, P<0.001). In Kaplan–Meier Survival analysis, there was no difference in the mortality rate between kidney stage I and stage II, whereas the mortality increased with worsening renal function (Fig. 1A). Similarly, when stratifying the patients according to the quintiles of the serum sodium level, patients in 1st and 2nd quintiles had a higher 12-month mortality, whereas there was no difference between 3rd to 5th quintile (Fig. 1B).

In ROC curve analysis, the best cutoff value of GFR to predict the 12-month mortality was 60 mL/min/1.73 m² with a sensitivity, a specificity, and an area under the curve (AUC) of 0.56, 0.68, and 0.63 (95% confidence interval [CI], 0.59–0.68, P<0.001), respectively. As for the serum sodium level, the best cutoff value was 138 mmol/L with a sensitivity, a specificity, and an AUC of 0.67, 0.51, and 0.60 (95% CI 0.56–0.64, P<0.001), respectively (Fig. 2). The 12-month mortality rate was higher in the RI group than in those without (22.8% vs. 10.9%, P<0.001). After adjustment, RI was associated with a 40% increase in 12-month mortality (adjusted HR, 1.40, 95% CI 1.20–1.63). In total, 676 patients (46%) had a low serum sodium level. The clinical outcomes including in-hospital death, 12-month mortality, 12-month rehospitalization, and 12-month composite of mortality and rehospitalization were higher in patients with RI and low sodium level (Table 2).

There was only a week correlation between GFR and serum sodium level (Pearson’s r=0.115, P<0.001). When classifying the patients according to renal function and serum sodium level, the 12-month mortality rate was lowest in patients with normal renal function and high sodium level (7.1%), but highest in patients with RI and low sodium level (26.1%) (log-rank P<0.001), whereas there was no difference between patients with normal renal function and low sodium level (16.7%) and those with RI and high sodium level (18.9%) (log-rank P=0.585) (Fig. 3). In the Cox-proportional hazard regression analysis, patients with both RI and low sodium level had a 3.8-times increased hazard for 12-month mortality (HR, 3.80; 95% CI, 2.06–7.05), whereas a low sodium level (HR, 2.95; 95% CI, 1.51–5.73) and RI (HR 3.08; 95% CI, 1.63–5.82) had similar hazard ratio, suggesting they might be equivalent risk factors (Table 3).

4. Discussion

In this study, we showed that in hospitalized HF patients the 12-month mortality increased as renal function and serum sodium level decreased. Half of the patients had RI and those with the low serum sodium level were at the highest risk for 12-month mortality. There existed a very weak correlation between renal function and serum sodium level. Both RI and low sodium level were independent predictors of worse clinical outcomes with similar effect size, suggesting both may be equivalent risk factors. To the best of our knowledge, this is the
first study which investigated the prognostic value of RI stratified by the serum sodium level in hospitalized HF patients. As HF is a disease of the elderly, many of the HF patients have other accompanying comorbidities. Among them, RI frequently coexists with HF.[7,12] In this study, only 18% of the patients had normal renal function defined as Kidney Stage I, whereas the majority of the patients had some degree of renal dysfunction. This is similar to the study result, where only 17% of HF patients had creatinine clearance >90mL/min/1.73 m².[113] Thus, renal dysfunction is the rule rather than the exception in hospitalized HF patients. National Kidney Foundation defines mild renal dysfunction with a reduction of GFR <90mL/min/1.73 m² (stage II). We demonstrated that there was no difference in 12-month mortality between kidney stage I and II, whereas the 12-month mortality increased with worsening kidney stages (III–V). This finding indicates a threshold effect of GFR, suggesting no risk increase above this threshold.[114] It also implies a dose–response relationship below the threshold and may be an indirect evidence for the causality between renal function and clinical outcomes.

The low serum sodium level has been reported as a risk factor for worse clinical outcomes.[115–117] We showed that there was a very weak correlation between GFR and serum sodium level. Both RI and low sodium level have been associated with advanced HF. The low serum sodium level has been reported as a risk factor for worse clinical outcomes.[115–117] We showed that there was a very weak correlation between GFR and serum sodium level. Both RI and low sodium level have been associated with advanced HF.

### Table 1

Baseline characteristics according to renal function.

|                           | Stage II (n = 746, 51%) | Stage III–IV (n = 716, 49%) | P-value | Na–median (n = 676, 46%) | Na+–median (n = 746, 53%) | P-value |
|---------------------------|------------------------|-----------------------------|---------|-------------------------|--------------------------|---------|
| Age (years)               | 61.4 ± 15.0            | 71.5 ± 12.7                 | <0.001  | 66.8 ± 14.7             | 65.9 ± 14.8              | 0.272   |
| - age >65 years           | 44.6%                  | 72.5%                       | <0.001  | 60.2%                   | 56.6%                    | 0.165   |
| Men                       | 71.4%                  | 61.5%                       | <0.001  | 66.9%                   | 66.3%                    | 0.815   |
| Current smoker            | 23.9%                  | 16.9%                       | 0.001   | 21.3%                   | 19.7%                    | 0.455   |
| Body mass index (kg/m²)   | 23.8 ± 4.5             | 23.9 ± 4.1                  | 0.310   | 23.5 ± 4.1              | 24.2 ± 4.4               | 0.016   |
| Past medical history      |                        |                             |         |                         |                          |         |
| Diabetes mellitus         | 22.1%                  | 42.8%                       | <0.001  | 37.5%                   | 27.9%                    | <0.001  |
| Hypertension              | 39.0%                  | 62.6%                       | <0.001  | 50.8%                   | 51.6%                    | 0.091   |
| Chronic kidney disease    | 12.8%                  | 22.2%                       | <0.001  | 14.0%                   | 10.8%                    | 0.059   |
| Dyslipidemia              | 8.9%                   | 15.0%                       | <0.001  | 13.1%                   | 10.8%                    | 0.113   |
| Coronary artery disease   | 12.9%                  | 23.7%                       | <0.001  | 19.1%                   | 17.6%                    | 0.182   |
| Congestive heart failure  | 12.4%                  | 23.1%                       | <0.001  | 20.1%                   | 15.6%                    | 0.032   |
| Atrial fibrillation       | 13.1%                  | 14.0%                       | 0.657   | 11.9%                   | 11.1%                    | 0.190   |
| Dilated cardiomyopathy    | 5.2%                   | 4.1%                        | 0.342   | 5.0%                    | 4.4%                     | 0.177   |
| Valvular heart disease    | 4.2%                   | 4.0%                        | 0.631   | 4.1%                    | 4.1%                     | 0.191   |
| Myocarditis               | 0.7%                   | 0.2%                        | 0.187   | 0.3%                    | 0.4%                     | 0.183   |
| Stroke                    | 4.9%                   | 7.6%                        | 0.040   | 7.0%                    | 5.6%                     | 0.127   |
| Chronic obstructive lung disease | 3.9% | 5.0% | 0.337 | 5.2% | 3.8% | 0.110 |
| Ischemic causes for heart failure | 39.8% | 51.4% | <0.001 | 46.9% | 44.3% | 0.316 |
| NYHA functional class     |                        |                             | 0.006   |                         |                          | 0.195   |
| I                         | 2.1%                   | 1.6%                        |         | 2.3%                    | 1.5%                     |         |
| II                        | 24.8%                  | 20.0%                       |         | 20.0%                   | 24.7%                    |         |
| III                       | 51.9%                  | 48.0%                       |         | 50.2%                   | 50.2%                    |         |
| IV                        | 21.2%                  | 30.4%                       |         | 27.5%                   | 23.5%                    |         |
| Physical exam             |                        |                             |         |                         |                          |         |
| Systolic blood pressure (mm Hg) | 123.8 ± 24.1 | 131.5 ± 30.5 | <0.001 | 124.7 ± 28.6 | 130.2 ± 26.6 | <0.001 |
| Diastolic blood pressure (mm Hg) | 77.4 ± 16.0 | 78.1 ± 18.5 | 0.537 | 75.8 ± 17.9 | 79.4 ± 16.5 | <0.001 |
| Heart rate (beats/min)    | 88.4 ± 22.9            | 92.4 ± 25.2                 | <0.001  | 91.4 ± 25               | 89.5 ± 23.3              | 0.098   |
| Laboratory findings       |                        |                             |         |                         |                          |         |
| Sodium (mmol/L)           | 138.8 ± 44.4           | 137.7 ± 4.8                 | <0.001  | 134.6 ± 3.8             | 141.5 ± 2.3              | <0.001  |
| Potassium (mmol/L)        | 4.2 ± 0.5              | 4.4 ± 0.8                   | <0.001  | 4.4 ± 0.7               | 4.2 ± 0.6                | <0.001  |
| GFR (mL/min/1.73 m²)      | 84.2 ± 20.0            | 38.6 ± 15.4                 | <0.001  | 56.6 ± 28.4             | 66.5 ± 28.7              | <0.001  |
| Creatinine (mg/dL)        | 36.2 ± 42.6            | 25.7 ± 53.8                 | <0.001  | 28.0 ± 49               | 33.7 ± 48.4              | 0.666   |
| Blood urea nitrogen (mg/dL) | 16.4 ± 44.7 | 33.0 ± 22.9 | <0.001 | 27.6 ± 27.3 | 22.3 ± 43.3 | <0.001 |
| Ejection fraction (%)     | 31.4 ± 8.0             | 30.4 ± 8.3                  | 0.030   | 30.2 ± 8.4              | 31.6 ± 7.9               | 0.004   |
| Medications               |                        |                             |         |                         |                          |         |
| Remin–angiotensin–aldosterone inhibitor | 52.7% | 31.7% | <0.001 | 36.7% | 47.3% | <0.001 |
| Beta-blocker              | 41.2%                  | 25.4%                       | <0.001  | 29.6%                   | 36.8%                    | 0.014   |
| Mineralocorticoid receptor antagonist | 46.8% | 26.2% | <0.001 | 33.0% | 39.8% | 0.008 |
| Furosemide                | 64.3%                  | 67.5%                       | 0.209   | 64.9%                   | 66.7%                    | 0.472   |
| Hydrochlorothiazide       | 2.7%                   | 1.8%                        | 0.056   | 1.5%                    | 2.9%                     | 0.177   |
| Digoxin                   | 27.6%                  | 17.0%                       | <0.001  | 21.4%                   | 23.4%                    | 0.271   |
| Calcium channel blocker   | 6.7%                   | 13.7%                       | <0.001  | 8.4%                    | 11.6%                    | 0.132   |

**Note:** New York Heart Association.
disease in other organ through common hemodynamic, neuro-hormonal, and inflammatory feedback pathway: upregulation of the RAAS, enhancement of sympathetic nerve stimulation, and increase in proinflammatory factors. It is not clear, whether RI is a marker for or a mediator of worsening HF. If it was a “mediator,” cardio-renal pathophysiologic pathways could be an important target for preventing worsening HF.

Similarly, both neuro-humoral overactivation and nonosmotic release of vasopressin due to decreased effective circulating volume contribute to development of hyponatremia. Consequently, hyponatremia is observed in more advanced HF patients. The role of hyponatremia as a mediator is still controversial; the correction of hyponatremia during hospital admission was not associated with improved outcomes in 2 retrospective cohort studies whereas its correction with AVP antagonist showed improved outcomes in a post-hoc analysis of a randomized clinical trial.

Despite high prevalence of RI, only 12% of the patients reported having chronic kidney disease in their history taking. Considering the substantial impact of RI in HF patients, this discrepancy mandates routine measurement of GFR in all HF patients and to incorporate renal function into risk stratification.

The overall prescription rate of RAAS inhibitor, beta blocker, and mineralocorticoid receptor antagonist was 67%, 57%, and 55% at the hospital discharge. However, there exist a clear trend for underprescription in patients with RI and low sodium level. RAAS inhibition has been the mainstay of HF-therapy and has proven reno-protective effect in patients with hypertension and diabetic nephropathy. Furthermore, RAAS inhibition

### Table 2

|                  | I/II (n=746) | III-V (n=716) | P-value | Interaction |
|------------------|--------------|--------------|---------|-------------|
| In-hospital death| 2.0%         | 6.8%         | <0.001  | 0.324       |
| Na < median      | 3.4%         | 8.4%         | <0.001  | 0.008       |
| Na ≥ median      | 1.1%         | 5.1%         | <0.001  |             |
| P-value          | 0.028        | 0.036        |         |             |
| 12-month death   | 10.9%        | 22.8%        | <0.001  | 0.066       |
| Na < median      | 16.7%        | 26.1%        | 0.001   |             |
| Na ≥ median      | 7.1%         | 18.9%        | <0.001  |             |
| P-value          | <0.001       | 0.022        |         |             |
| 12-month rehospitalization | 22.1% | 34.6% | <0.001 | 0.848 |
| Na < median      | 27.0%        | 38.9%        | 0.001   |             |
| Na ≥ median      | 19.0%        | 29.7%        | <0.001  |             |
| P-value          | 0.010        | 0.010        |         |             |
| 12-month death and rehospitalization | 30.7% | 49.6% | <0.001 | 0.214 |
| Na < median      | 39.9%        | 54.6%        | <0.001  |             |
| Na ≥ median      | 24.7%        | 43.8%        | <0.001  |             |
| P-value          | <0.001       | 0.004        |         |             |

The median of sodium level was 139 mmol/L.
According to K/DOQI clinical practice guidelines, thiazide diuretics are recommended in patients with normal renal function and high sodium level but highest in patients with renal impairment (RI) and low sodium level, whereas there was no difference between patients with normal renal function and low sodium level and those with RI and high sodium level.[23,24] Therefore, despite the independent predictor of 12-month death.

There was a week correlation between GFR and serum sodium level (Pearson’s r<0.001 0.003 0.007). Loop diuretics have lower hyponatremic risk than thiazide-type diuretics because they inhibit sodium chloride reabsorption in the thick ascending limb of the loop of Henle, leading to impaired generation of the hyperosmotic gradient in the medullary interstitium. Consequently, the responsiveness to antidiuretic hormone is reduced. The opposite is for thiazide-type diuretics. In our study group, the usage of thiazide diuretics did not differ between patients with high and those with low serum sodium level, suggesting that causes other than diuretics may be responsible for the different serum sodium levels.

The main limitation of the present study is the COAST study was not a prospective, randomized trial. Although we tried to adjust for significant clinical variables, unmeasured confounding factors may have biased the study result. Furthermore, a single measurement would not fully describe the patient’s condition in this highly vulnerable and dynamic phase of acute decompensation. Serial measurement would better describe the patient’s reserve capacity to recover from acute decompensation.

In conclusion, hospitalized HF patients both RI and low serum sodium level are independent predictors of worse clinical outcomes. Especially, RI patients with low serum sodium level are at the highest risk and need meticulous medical care in hospitalized HF patients.

**Table 3**

| Independent predictor of 12-month death | P-value | HR | 95% confidence interval |
|----------------------------------------|---------|----|------------------------|
| Smoking                                | 0.009   | 0.45 | 0.25–0.82              |
| Body mass index (kg/m²)               | <0.001  | 0.88 | 0.84–0.93              |
| Hypertension                          | 0.040   | 1.54 | 1.02–2.33              |
| NYHA Class                             | <0.001  | 1.82 | 1.56–2.44              |
| Diastolic blood pressure (mmHg)       | <0.001  | 0.98 | 0.97–0.99              |
| RI (+), Na ≥ median (reference)       | 1.0     |    |                        |
| RI (+), Na < median                   | 0.002   | 2.95 | 1.51–5.75              |
| RI (+), Na ≥ median                   | <0.001  | 3.08 | 1.63–5.62              |
| RI (+), Na < median                   | <0.001  | 3.80 | 2.06–7.05              |

Co-Propotional Hazard ratio, forward conditional Variables associated with 12-month mortality with P<0.05 were included: age in decade, current smoking, body mass index, diabetes melitus, hypertension, coronary artery disease, stroke, chronic obstructive lung disease. New York Heart Association functional class, the use of rennin-angiotensin-aldosterone inhibitor, beta blocker, calcium channel blocker, oral furosemide, mineralocorticoid antagonist, and dobutamine, diastolic blood pressure, potassium level, and renal impairment. HR hazard ratio, NYHA=New York Heart Association, RI=renal impairment.

**Figure 3.** 12-month mortality according to renal function and serum sodium level. The 12-month mortality rate was lowest in patients with normal renal function and high sodium level but highest in patients with renal impairment (RI) and low sodium level, whereas there was no difference between patients with normal renal function and low sodium level and those with RI and high sodium level (A). There was a week correlation between GFR and serum sodium level (Pearson’s r=0.115, P<0.001) (B). GFR=glomerular filtration rate, RI=renal impairment.

**References**

[1] Gheorghiade M, Abraham WT, Albert NM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J 2007;28:980–8.

[2] Klein L, O’Connor CM, Leimberger JD, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 2005;111:2454–60.

[3] Kearney MT, Fox KA, Lee AJ, et al. Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. J Am Coll Cardiol 2002;40:1801–8.

[4] Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998;9(12 Suppl):S16–23.

[5] Smith GL, Lichtenma JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006;47:1987–96.

[6] Heywood JT, Fonarow GC, Costanzo MR, et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 2007;13:60–6.

[7] Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209–16.
Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000;102:203–10.

Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004;43:61–7.

Yoo BS, Park JJ, Choi DJ, et al. Prognostic value of hyponatremia in heart failure patients: an analysis of the Clinical Characteristics and Outcomes in the Relation with Serum Sodium Level in Asian Patients Hospitalized for Heart Failure (COAST) study. Korean J Intern Med 2015;30:460–70.

Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137–47.

Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006;27:2725–36.

McAlister FA, Ezekowitz J, Tonelli M, et al. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004;109:1004–9.

Shlipak MG, Katz R, Fried LF, et al. Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol 2005;45:268–71.

Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. Circulation 2010;121:2592–600.

Spasovski G, Vahnholder R, Allocco B, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol 2014;170:G1–47.

Lee SE, Choi DJ, Yoon CH, et al. Improvement of hyponatraemia during hospitalisation for acute heart failure is not associated with improvement of prognosis: an analysis from the Korean Heart Failure (KorHF) registry. Heart 2012;98:1798–804.

Konstam MA, Gheorghiade M, Burnett JCJr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297:1319–31.

Lewis EJ, Hanssicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:2136–62.

Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667–75.

Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777–81.

Kittleson M, Hurwitz S, Shah MR, et al. Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. J Am Coll Cardiol 2003;41:2029–35.

Shlipak MG. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med 2003;138:917–24.

Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111:1487–91.

Smith GL, Shlipak MG, Havranek EP, et al. Race and renal impairment in heart failure: mortality in blacks versus whites. Circulation 2005;111:1270–7.

Krumholz HM, Chen YT, Vaccarino V, et al. Correlates and impact on outcomes of worsening renal function in patients > or = 65 years of age with heart failure. Am J Cardiol 2000;85:1110–3.

Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 2014;63:713–35.